Swiss biotech Windward Bio raises $165 million to launch Phase 3 asthma trial for China-derived drug
read at Endpoints ↗DealPositive
Swiss biotech Windward Bio announced it has secured $165 million in financing.
The capital will be used to move one of its two experimental medicines, originally discovered in China, into a Phase 3 clinical trial for asthma.
The company also retains an in-house discovery team that continues to develop additional candidates, underscoring its dual strategy of leveraging external assets and internal research.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial”
read at Endpoints ↗89 words · retrieved May 4
comments(0)
5-min edit window · permanent after that